Toronto, Ontario – April 21, 2026 - PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended February 28, 2026. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.PharmAla.ca and its profile page on SEDAR+ at www.sedarplus.ca.
“PharmAla’s financial position continues to benefit from an operational focus by the Company’s management,” said Nick Kadysh, Founding CEO. “PharmAla continues to be the only Psychedelics company that has worked to understand and continually improve commercial implications, in Australia and beyond; As Psychedelics advance rapidly towards commercialization globally, this operational know-how will become only more valuable.”
Financial Highlights:
- Customer deposits have continued to grow by $310,719 through Q2, offset by recognition of revenue of $181,492. These deposits, generally being 50% of the total contract value, can be recognized along with the remaining revenue when the related product is shipped, which for many customers requires the issuance of their clinical trial and/or import permits from relevant regulatory bodies.
- Revenues for the three and six months ended February 28, 2026 were $220,584 and $487,024 compared to $145,657 and $202,954 for the three and six months ended February 28, 2025.
- Net loss and comprehensive loss for the three and six months ended February 28, 2026 were $337,696 and $747,391 compared to $810,766 and $1,289,875 for the three and six months ended February 28, 2025.
- Cash used in operating activities was $366,396 for the six months ended February 28, 2026 compared to $491,721 for the six months ended February 28, 2025.
“Through Q2 2026, we have continued to see increased demand for our product, culminating in a steady increase in customer deposits,” said Will Avery, CFO, PharmAla Biotech. “With our proven supply chain in the U.S. and Australia we have been able to convert customer deposits into revenue at an improved rate.”
Issuance of Options:
PharmAla has issued options to the following Board Members and Officers. The options are issued subject to a vesting period, such that every 3 months 25% of the allotment will be vested, such that the options shall be fully vested on the 12 month anniversary of the date of grant, which is April 20, 2026. The options have a fixed exercise price per share of $0.10 (subject to adjustment in accordance with the terms of the Plan and/or stock option agreement). All vested but unexercised options shall expire and cease to be of effect on April 20, 2031.
Name of Optionee Position Number of Options
Jodi Butts Director 350,000
Kevin Roy Director 250,000
Fraser Macdonald Director 250,000
Perry Tsergas Director 250,000
Lennie Ryer Director 250,000
Nicholas Kadysh. Chief Executive Officer 1,000,000
Will Avery Chief Financial Officer 1,000,000
Farnoud Kazemzadeh Chief Operating Officer 1,000,000
Harpreet Kaur Employee 500,000
Total 4,850,000
Corporate Leadership Change
The Company regretfully announces that Ali Taghva will transition out of his role as Chief Commercial Officer to focus on other projects. Mr. Taghva will leave the role of Chief Commercial Officer effective immediately, and will fully transition out of the company by July 2026.
PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.
Nicholas Kadysh, CEO
press@pharmala.ca